Net ZERO Reverse uses a one-way airline lease model and ocean freight for returning empty containers, offering cost savings, operational efficiency, and large-scale emissions reduction.

Richard Ettl, CEO of SkyCell
“Pharma supply chains are at an inflection point. CO₂e has become a key criterion as companies work toward net-zero targets. Net ZERO Reverse dramatically cuts emissions while improving logistics efficiency and reducing costs.”

‍

Pharmaceutical shipments are transported via air in SkyCell’s hybrid containers, which already reduce CO₂ emissions by up to 50% compared to traditional containers. These containers ensure zero product loss and a temperature excursion rate below 0.05%, guaranteeing product safety.

Once shipments reach their destination, empty containers return via low-emission ocean freight, managed by SkyCell and its freight partners. This method reduces emissions by over 90% compared to the equivalent journey via air freight, according to DECARBONIZE calculations using MIT’s CO₂e methodology. Any remaining emissions are offset through high-quality permanent removal projects, achieving net-zero reverse logistics.

For instance, on a Chicago-to-Sydney route, a SkyCell 1500X hybrid container avoids 18 tons of CO₂e compared to the RKN and 10 tons compared to the RAP, delivering total savings of 15 to 28 tons of CO₂e per pallet.
‍

SkyCell’s Net ZERO Reverse sets a new standard for sustainable pharma logistics by eliminating the need to fly empty containers, simplifying operations, and cutting emissions. On any shipping lane, airlines can avoid the entire return journey’s CO₂ emissions.

By offering a scalable, low-cost solution, Net ZERO Reverse delivers measurable benefits for all stakeholders, supporting both operational efficiency and global sustainability goals. SkyCell continues to lead innovation, providing greater value to pharmaceutical clients while advancing the industry toward a more environmentally responsible future.